Combination Antiretroviral Therapy With Raltegravir Leads to Rapid Immunologic Reconstitution in Treatment-Naive Patients With Chronic HIV InfectionPALLIKKUTH, Suresh; FISCHL, Margaret A; PAHWA, Savita et al.The Journal of infectious diseases. 2013, Vol 208, Num 10, pp 1613-1623, issn 0022-1899, 11 p.Article

Immune Exhaustion Occurs Concomitantly With Immune Activation and Decrease in Regulatory T Cells in Viremic Chronically HIV-1―Infected PatientsSACHDEVA, Meenakshi; FISCHL, Margaret A; PAHWA, Rajendra et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 54, Num 5, pp 447-454, issn 1525-4135, 8 p.Article

Do HIV type 1 RNA levels provide additional prognostic value to CD4⁺ T lymphocyte counts in patients with advanced HIV type 1 infection?ARDUINO, Jean Marie; FISCHL, Margaret A; STANLEY, Kenneth et al.AIDS research and human retroviruses. 2001, Vol 17, Num 12, pp 1099-1105, issn 0889-2229Article

HIV-1 Amino Acid Changes Among Participants With Virologic Failure: Associations With First-line Efavirenz or Atazanavir Plus Ritonavir and Disease StatusMOLLAN, Katie; DAAR, Eric S; SAX, Paul E et al.The Journal of infectious diseases. 2012, Vol 206, Num 12, pp 1920-1930, issn 0022-1899, 11 p.Article

Abacavir/Lamivudine Versus Tenofovir DF/ Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final ResultsSAX, Paul E; TIERNEY, Camlin; FARAJALLAH, Awny et al.The Journal of infectious diseases. 2011, Vol 204, Num 8, pp 1191-1201, issn 0022-1899, 11 p.Article

Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 TherapySAX, Paul E; TIERNEY, Camlin; FARAJALLAH, Awny et al.The New England journal of medicine. 2009, Vol 361, Num 23, pp 2230-2240, issn 0028-4793, 11 p.Article

Antiretroviral Treatment of Adult HIV Infection : 2008 Recommendations of the International AIDS Society-USA PanelHAMMER, Scott M; ERON, Joseph J; JACOBSEN, Donna M et al.JAMA, the journal of the American Medical Association. 2008, Vol 300, Num 5, pp 555-570, issn 0098-7484, 16 p.Article

Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapyMOORE, Jeff D; ACOSTA, Edward P; JOHNSON, Victoria A et al.Antiviral therapy (London). 2007, Vol 12, Num 6, pp 981-986, issn 1359-6535, 6 p.Article

Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimenFISCHL, Margaret A; COLLIER, Ann C; BASSETT, Roland et al.AIDS (London). 2007, Vol 21, Num 3, pp 325-333, issn 0269-9370, 9 p.Article

Interferon-α2b with protease inhibitor-based antiretroviral therapy in patients with aids-associated Kaposi sarcoma : An AIDS malignancy consortium phase I trialKROWN, Susan E; LEE, Jeannette Y; LAN LIN et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 41, Num 2, pp 149-153, issn 1525-4135, 5 p.Article

Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infectionHIRSCH, Martin S; STEIGBIGEL, Roy T; LEAVITT, Randi Y et al.Clinical infectious diseases. 2003, Vol 37, Num 8, pp 1119-1124, issn 1058-4838, 6 p.Article

Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliterDEMETER, Lisa M; BOSCH, Ronald J; FISCHL, Margaret A et al.Journal of clinical microbiology (Print). 2002, Vol 40, Num 6, pp 2089-2094, issn 0095-1137Article

HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapyIMAMICHI, Hiromi; DEGRAY, Gerald; ASMUTH, David M et al.AIDS (London). 2011, Vol 25, Num 2, pp 159-164, issn 0269-9370, 6 p.Article

Therapeutic Drug Monitoring of Protease Inhibitors and Efavirenz in HIV-Infected Individuals With Active Substance-Related DisordersQING MA; ZINGMAN, Barry S; LUQUE, Amneris E et al.Therapeutic drug monitoring. 2011, Vol 33, Num 3, pp 309-314, issn 0163-4356, 6 p.Article

Antiviral Activity of Single-Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV-Infected AdultsJACOBSON, Jeffrey M; SAAG, Michael S; MURGA, Jose D et al.The Journal of infectious diseases. 2008, Vol 198, Num 9, pp 1345-1352, issn 0022-1899, 8 p.Article

Buprenorphine assay and plasma concentration monitoring in HIV-infected substance usersDIFRANCESCO, Robin; FISCHL, Margaret A; DONNELLY, Julie et al.Journal of pharmaceutical and biomedical analysis. 2007, Vol 44, Num 1, pp 188-195, issn 0731-7085, 8 p.Article

A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapyCOLLIER, Ann C; RIBAUDO, Heather; MUKHERJEE, A. Lisa et al.The Journal of infectious diseases. 2005, Vol 192, Num 8, pp 1398-1406, issn 0022-1899, 9 p.Article

Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjectsDICENZO, Robert; FORREST, Alan; FISCHL, Margaret A et al.Antimicrobial agents and chemotherapy. 2004, Vol 48, Num 3, pp 918-923, issn 0066-4804, 6 p.Article

Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society-USA panelYENI, Patrick G; HAMMER, Scott M; MONTANER, Julio S. G et al.JAMA, the journal of the American Medical Association. 2002, Vol 288, Num 2, pp 222-235, issn 0098-7484Article

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1: A Randomized TrialDAAR, Eric S; TIERNEY, Camlin; FARAJALLAH, Awny et al.Annals of internal medicine. 2011, Vol 154, Num 7, pp 445-456, issn 0003-4819, 12 p.Article

Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected PatientsROSS, Lisa L; WEINBERG, Winkler G; DEJESUS, Edwin et al.AIDS research and human retroviruses. 2010, Vol 26, Num 4, pp 407-417, issn 0889-2229, 11 p.Article

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: Results of a prospective randomized trial (AIDS Clinical Trial Group 5125s)TEBAS, Pablo; JIAMENG ZHANG; SATTLER, Fred et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 45, Num 2, pp 193-200, issn 1525-4135, 8 p.Article

Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 diseaseMALHOTRA, Uma; BOSCH, Ronald J; CHAN, Ellen et al.The Journal of infectious diseases. 2004, Vol 189, Num 3, pp 515-519, issn 0022-1899, 5 p.Article

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus diseaseFISCHL, Margaret A; RIBAUDO, Heather J; MORSE, Gene D et al.The Journal of infectious diseases. 2003, Vol 188, Num 5, pp 625-634, issn 0022-1899, 10 p.Article

Twice-daily Trizivir versus combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: A formulation-switch trialFISCHL, Margaret A; BURNSIDE, Alfred F; FARTHING, Charles F et al.Pharmacotherapy. 2003, Vol 23, Num 11, pp 1432-1440, issn 0277-0008, 9 p.Article